Inventor

LIANG YANKE

US41 patents

⚠️ This page may combine multiple inventors who share the name “LIANG YANKE”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.

LIANG YANKE

C4 THERAPEUTICS INC

Spirocyclic degronimers for target protein degradation

Heterocyclic degronimers for target protein degradation

Spirocyclic degronimers for target protein degradation

Heterocyclic degronimers for target protein degradation

C3-carbon linked glutarimide degronimers for target protein degradation

N/O-linked Degrons and Degronimers for protein degradation

Isoindolinone and indazole compounds for the degradation of EGFR

Substituted piperidine Degronimers for Target Protein degradation

C3-carbon linked glutarimide degronimers for target protein degradation

Isoindolinone and indazole compounds for the degradation of EGFR

Isoindolinone and indazole compounds for the degradation of EGFR

N/O-linked degrons and degronimers for protein degradation

N/O-linked degrons and degronimers for protein degradation

Heterocyclic degronimers for target protein degradation

Spirocyclic degronimers for target protein degradation

Therapeutics for the degradation of mutant BRAF

BRAF degraders

Targeted protein degradation

Bicyclic-substituted glutarimide cereblon binders

DANA FARBER CANCER INST INC

Imidazolyl kinase inhibitors and uses thereof

Inhibitors of cyclin-dependent kinase 7 (CDK7)

Macrocyclic kinase inhibitors and uses thereof

Imidazolyl kinase inhibitors and uses thereof

Uses of salt-inducible kinase (SIK) inhibitors

Degradation of cyclin-dependent kinase 4/6 (CDK4/6) by conjugation of CDK4/6 inhibitors with E3 ligase ligand and methods of use

Imidazolyl kinase inhibitors and uses thereof

Inhibitors of cyclin-dependent kinase 7 (CDK7)

Degradation of cyclin-dependent kinase 8 (CDK8) by conjugation of CDK8 inhibitors with E3 ligase ligand and methods of use

Degradation of cyclin-dependent kinase 8 (CDK8) by conjugation of CDK8 inhibitors with E3 ligase ligand and methods of use

Degradation of cyclin-dependent kinase 8 (CDK8) by conjugation of CDK8 inhibitors with E3 ligase ligand and methods of use

Degradation of cyclin-dependent kinase 9 (CDK9) by conjugation of CDK9 inhibitors with E3 ligase ligand and methods of use

MASSACHUSETTS GEN HOSPITAL

Uses of pyrimidopyrimidinones as SIK inhibitors

Uses of pyrimidopyrimidinones as SIK inhibitors

Uses of salt-inducible kinase (SIK) inhibitors for treating osteoporosis

Uses of salt-inducible kinase (SIK) inhibitors for treating osteoporosis

HOFFMANN LA ROCHE

Isoindolinone derivatives as selective allosteric inhibitors of Egfr mutant cancers

2-benzopyrazinyl-n-heteroaryl-2-phenyl-acetamide compounds

2-benzopyrazinyl-n-heteroaryl-2-phenyl-acetamide compounds

BROAD INST INC

Bicyclic urea kinase inhibitors and uses thereof

Bicyclic urea kinase inhibitors and uses thereof

Bicyclic urea kinase inhibitors and uses thereof